Belatacept: Where the BENEFITS Outweigh the Risk
- PMID: 28434523
- DOI: 10.1053/j.ajkd.2017.02.007
Belatacept: Where the BENEFITS Outweigh the Risk
Comment on
-
Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.Am J Kidney Dis. 2017 May;69(5):587-594. doi: 10.1053/j.ajkd.2016.09.021. Epub 2016 Nov 23. Am J Kidney Dis. 2017. PMID: 27889299 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources

